Royce & Associates LP Makes New Investment in SOPHiA GENETICS SA $SOPH

Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 430,257 shares of the company’s stock, valued at approximately $2,009,000. Royce & Associates LP owned about 0.64% of SOPHiA GENETICS as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of the stock. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $49,000. Green Alpha Advisors LLC increased its position in shares of SOPHiA GENETICS by 10.8% during the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock valued at $213,000 after purchasing an additional 4,444 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $212,000. Susquehanna International Group LLP bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $88,000. Finally, Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $49,000. Institutional investors own 31.59% of the company’s stock.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 17,473 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $5.00, for a total value of $87,365.00. Following the completion of the sale, the chief executive officer directly owned 3,646,967 shares in the company, valued at approximately $18,234,835. This represents a 0.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 193,859 shares of company stock valued at $943,777. 4.88% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $7.50.

SOPHiA GENETICS Price Performance

SOPH opened at $5.05 on Friday. The business has a fifty day moving average of $4.94 and a 200 day moving average of $4.84. SOPHiA GENETICS SA has a 52-week low of $2.59 and a 52-week high of $5.70. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The stock has a market cap of $345.85 million, a P/E ratio of -9.71 and a beta of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.